迈维代谢 is an innovative medical metabolic-technology developer that focuses on applying metabolomics technologies in life-science research and medical health. The company operates eight ABSciex liquid chromatography–mass spectrometry (LC‑MS) systems, two Agilent LC‑MS/GC‑MS systems and a Dell high‑performance computing platform. It provides services to agriculture breeding and precision medicine fields. The company recently completed a Series B financing led by Haida Investment. Proceeds will be used to expand the company's business layout, increase product and technology R&D investment, and advance automation upgrades for key projects. (Source: IT桔子 / DoNews) 迈维代谢 is a Wuhan-based company focused on metabolomics testing services, technology innovation, and clinical diagnostic applications. Its business includes CRO metabolomics services, development of tumor early‑screening “liquid biopsy” metabolite reagent kits, and prognostic kits for chronic metabolic diseases. The company maintains nearly 20,000 m² of laboratory space, about 40 mass‑spectrometers, and a 350‑person CT+BT+IT team, with R&D staff comprising 60% of headcount. It has built a metabolomics database of 2.2 million metabolites and developed high‑throughput, ultra‑sensitive, broad‑coverage targeted metabolomics methods and metabolite biomarker machine‑learning algorithms. Its services already cover 34 provinces and serve over 2,000 institutional and clinical customers. The company plans to use new funding to build an innovative metabolomics team, expand core technology and market leadership, strengthen small‑molecule clinical product R&D, enrich its product pipeline, and accelerate development of its clinical mass‑spectrometry platform.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2021